Search

Search Results

• COST-EFFECTIVENESS OF POST-AUTOTRANSPLANT LENALIDOMIDE IN PERSONS WITH MULTIPLE MYELOMA.

  Monia Marchetti , Robert Peter Gale, Giovanni Barosi

  Page e2021034

  2021-04-29

  https://doi.org/10.4084/MJHID.2021.034

  1611

  PDF: 598

  HTML: 261

• Guest Editor: Pellegrino Musto HOW FIRST LINE THERAPY IS CHANGING IN TRANSPLANT-ELIGIBLE MULTIPLE MYELOMA PATIENTS

  Yasmine Houbaida, Maria Livia Del Giudice, Sara Galimberti, Gabriele Buda

  e2025026

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.026

  2115

  PDF: 1761

  HTML: 449

• Dose-modified lenalidomide induces sustained hematological response in patients with intermediate to high risk myelodysplasia

  Alhossain A. Khalafallah, Bernadene Fernandopulle, Terry Brain

  e2010012

  2010-05-31

  https://doi.org/10.4084/mjhid.2010.012

  1124

  PDF: 730

  HTML: 381

• Guest Edtor: Pellegrino Musto NOVELTIES ON MULTIPLE MYELOMA FROM THE MAIN 2024 HEMATOLOGY CONFERENCES

  Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Antonella Poloni, Massimo Offidani

  e2025027

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.027

  1559

  PDF: 1335

  HTML: 600

• LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE

  Patrizia Tosi

  e2013037

  2013-06-03

  https://doi.org/10.4084/mjhid.2013.037

  1447

  PDF: 961

  HTML: 1305

  fig 1A: 236

  figure1B: 201

• Lenalidomide and temozolomide combination in a very elderly patient with CNS relapse of diffuse large b-cell lymphoma.

  Emanuele Cencini, Alberto Fabbri, Umberto Arrigucci, Alfonso Cerase, Monica Bocchia

  e2017040

  2017-06-16

  https://doi.org/10.4084/mjhid.2017.040

  3599

  PDF: 1115

  HTML: 1046

  Figure 1: 253

• RECENT ADVANCES IN THE 5Q- SYNDROME

  Andrea Pellagatti, Jacqueline Boultwood

  e2015037

  2015-05-20

  https://doi.org/10.4084/mjhid.2015.037

  3097

  PDF: 1928

  HTML: 3834

  Pellagatti Fig 1: 267

  Pellagatti Fig. 2: 254

• Diagnosis of del(5q) MDS, 14 years after JAK-2 positive PV appearance: complete remission of both diseases with lenalidomide monotherapy

  Antonella Vaccarino, Irene Dogliotti, Fabio Marletto, Andrea Demarchi, Mario Bazzan

  e2016050

  2016-10-20

  https://doi.org/10.4084/mjhid.2016.050

  2951

  PDF: 816

  HTML: 1315

  Blood Count trend before and during lenalidomide treatment: 237

  Light micrograph of bone marrow biopsy of a patient with PV and 5q deletion: 237

• INFECTIONS IN MYELODYSPLASTIC SYNDROME IN RELATION TO STAGE AND THERAPY

  Giuseppe Leone, Livio Pagano

  e2018039

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.039

  4459

  PDF: 1530

  HTML: 773

• Guest Editor: Pellegrino Musto HOW FIRST-LINE THERAPY IS CHANGING IN NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA PATIENTS.

  Daniele Derudas

  e2025025

  2025-02-27

  https://doi.org/10.4084/MJHID.2025.025

  1730

  PDF: 1460

  HTML: 184

• ELOTUZUMAB FOR THE TREATMENT OF RELAPSED OR REFRACTORY MULTIPLE MYELOMA, WITH SPECIAL REFERENCE TO ITS MODES OF ACTION AND SLAMF7 SIGNALING

  Masafumi Taniwaki, Mihoko Yoshida, Yosuke Matsumoto, Kazuho Shimura, Junya Kuroda, Hiroto Kaneko

  e2018014

  2018-02-15

  https://doi.org/10.4084/mjhid.2018.014

  5466

  PDF: 2025

  HTML: 2300

• POEMS SYNDROME: AN UPDATE

  Andrea Nozza

  e2017051

  2017-09-01

  https://doi.org/10.4084/mjhid.2017.051

  3516

  PDF: 1743

  HTML: 1800

• NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES

  Francesco D'Alò, Mariangela Greco, Marianna Criscuolo, Maria Teresa Voso

  e2010021

  2010-08-11

  https://doi.org/10.4084/mjhid.2010.021

  2116

  PDF: 1832

  HTML: 811

• THE TREATMENT OF MULTIPLE MYELOMA PATIENTS NOT ELIGIBLE FOR ASCT

  Paul Richardson, Jacob Laubach, Anuj Mahindra, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Noopur Raje, Nikhil Munshi, Kenneth Anderson

  e2010009

  2010-05-03

  https://doi.org/10.4084/mjhid.2010.009

  2133

  PDF: 786

  HTML: 676

• UPDATE ON THE ROLE OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA

  Patrizia Tosi, Manuela Imola, Mianulli Anna Maria, Simona Tomassetti, Anna Merli, Annalia Molinari, Serena Mangianti, Marina Ratta, Alessandro Isidori, Giuseppe Visani

  e2012069

  2012-11-05

  https://doi.org/10.4084/mjhid.2012.069

  2659

  PDF: 796

  HTML: 1654

• The THE PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW: PART 2-FOCUS ON THERAPY

  Michele Bibas

  e2024015

  2024-02-29

  https://doi.org/10.4084/MJHID.2024.015

  2561

  PDF: 1822

  HTML: 1068

• Effect of Immunoglobulin Therapy on the Rate of Infections in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation and or Treated with Immunomodulatory Agents

  Alhossain A. Khalafallah, Matthias Maiwald, Amanda Cox, Burns Denise, Gerald Bates, Terry Hannan, David Seaton, Bernadene Fernandopulle, Terry Brain

  e2010005

  2010-04-20

  https://doi.org/10.4084/mjhid.2010.005

  1241

  PDF: 614

  HTML: 1202

• Guest Editor: Pellegrino Musto AN UPDATE OF THE APPROPRIATE SEQUENCING FOR SALVAGE THERAPIES IN MULTIPLE MYELOMA

  Gregorio Barila', Francesca Rezzonico, Laura Pavan, Alessandro Corso, Renato Zambello

  e2025043

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.043

  1279

  PDF: 1026

  HTML: 474

• Brain abscesses caused by Nocardia paucivorans in a multiple myeloma patient treated with lenalidomide and dexamethasone: a case report and review of literature.

  Jacopo Monticelli, Roberto Luzzati, Cristina Maurel, Chiara Rosin, Romina Valentinotti, Claudio Farina

  e2015011

  2014-12-24

  https://doi.org/10.4084/mjhid.2015.011

  1783

  PDF: 1139

  HTML: 6568

  original file with images: 332

• THERAPY-RELATED MYELOID MALIGNANCIES IN MYELOMA

  Xenofon Papanikolaou, Bart Barlogie, Saad Usmani

  e2011047

  2011-10-24

  https://doi.org/10.4084/mjhid.2011.047

  2609

  PDF: 857

  HTML: 1755

• Single agent lenalidomide activity in multiple myeloma relapse evidenced uniquely by CT/PET

  Alessandro Gozzetti, Vania Rossi, Alfonso Cerase, Giulia Papini, Marzia Defina, Monica Bocchia

  e2012041

  2012-06-19

  https://doi.org/10.4084/mjhid.2012.041

  1200

  PDF: 804

  HTML: 769

• Ixazomib-associated skin exfoliation

  Yali Zhang, Long Zhao, Yuancheng Guo, bei liu

  e2022045

  2022-04-28

  https://doi.org/10.4084/MJHID.2022.045

  977

  PDF: 625

  HTML: 255

• APPLICATION OF NEW DRUGS IN CHRONIC LYMPHOCYTIC LEUKEMIA

  Tadeusz Robak

  e2010011

  2010-05-07

  https://doi.org/10.4084/mjhid.2010.011

  1740

  PDF: 697

  HTML: 2451

• PLASMA CELL LEUKEMIA UPDATE ON IMMUNOPHENOTYPE, MOLECULAR CHARACTERISTICS, AND THERAPY. The second part of plasma cell neoplasms with spreading in the blood and tissues Plasma Cell Leukemia

  Giuseppe G.M. Leone, Ugo Testa

  e2025080

  2025-10-31

  https://doi.org/10.4084/MJHID.2025.080

  1754

  PDF: 436

  Html: 267

• NOVEL DRUGS IN FOLLICULAR LYMPHOMA

  Giuseppe Rossi, Antonella Anastasia

  e2016061

  2016-11-01

  https://doi.org/10.4084/mjhid.2016.061

  5921

  PDF: 1604

  HTML: 1674

  Untitled: 281

• FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT

  Alessia Castellino, Umberto Vitolo

  e2017009

  2017-01-01

  https://doi.org/10.4084/mjhid.2017.009

  4728

  PDF: 1732

  HTML: 4319

  Tables and Images: 285

• "ROLE OF ALLOGENEIC TRANSPLANTATION IN MULTIPLE MYELOMA IN THE ERA OF NEW DRUGS"

  Benedetto Bruno, Luisa Giaccone, Moreno Festuccia, Mario Boccadoro

  e2010013

  2010-06-01

  https://doi.org/10.4084/mjhid.2010.013

  1570

  PDF: 713

  HTML: 1600

• LIGHT CHAIN AMYLOIDOSIS

  Paolo Milani, Giampaolo Merlini, Giovanni Palladini

  e2018022

  2018-03-01

  https://doi.org/10.4084/mjhid.2018.022

  6369

  PDF: 2460

  HTML: 1569

• THROMBOCYTOPENIA IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES - STILL AN UNSOLVED PROBLEM

  May Basood, Howard S. Oster, Moshe Mittelman

  e2018046

  2018-07-01

  https://doi.org/10.4084/mjhid.2018.046

  3369

  PDF: 1462

  HTML: 709

• Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA

  Michele Puppi, Ilaria Sacchetti, Katia Mancuso, Paola Tacchetti, Lucia Pantani, ilaria Rizzello, Miriam Iezza, Marco Talarico, Enrica Manzato, Simone Masci, Roberta Restuccia, Simona Barbato, Silvia Armuzzi, Barbara Taurisano, Ilaria Vigliotta, Elena Zamagni

  e2025045

  2025-04-30

  https://doi.org/10.4084/MJHID.2025.045

  1838

  PDF: 1385

  HTML: 661

• RECENT ADVANCES IN THE DEFINITION OF THE MOLECULAR ALTERATIONS OCCURRING IN MULTIPLE MYELOMA MOLECULAR ALTERATIONS OCCURRING IN MM

  Ugo Testa, Elvira Pelosi, Germana Castelli, Giuseppe Leone

  e2023062

  2024-06-29

  https://doi.org/10.4084/MJHID.2024.062

  1399

  PDF: 1145

  HTML: 270

• THE ROLE OF AUTOLOGOUS AND ALLOGENEIC STEM CELL TRANSPLANTATION IN FOLLICULAR LYMPHOMA IN THE NEW DRUGS ERA.

  Francesco Maura, Lucia Farina, Paolo Corradini

  e2016045

  2016-09-01

  https://doi.org/10.4084/mjhid.2016.045

  4210

  PDF: 1230

  HTML: 2118

  Fig.1: 246

  Fig. 2: 138

  Table 1: 250

  Table2: 272

  Table 3: 246

• SYSTEMIC FRONT LINE THERAPY OF FOLLICULAR LYMPHOMA: WHEN, TO WHOM AND HOW

  Francesca Pavanello, Sara Steffanoni, Michele Ghielmini, Emanuele Zucca

  e2016062

  2016-11-06

  https://doi.org/10.4084/mjhid.2016.062

  3918

  PDF: 1136

  HTML: 2558

• HEMATOPOIETIC CELL TRANSPLANTATION FOR OLDER PATIENTS WITH MDS

  Mazyar Shadman, Joachim Deeg

  e2014056

  2014-09-01

  https://doi.org/10.4084/mjhid.2014.056

  2211

  PDF: 839

  HTML: 3275

• REAL-WORLD OUTCOME IN THE PRE-CAR-T ERA OF MYELOMA PATIENTS QUALIFYING FOR CAR-T CELL THERAPY Real-world Assessment of Myeloma Patients as Candidates for CAR-T Therapy

  Ulrike Bacher, Simon Brechbühl, Barbara Jeker, Thomas Pabst

  e2021012

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.012

  1737

  PDF: 791

  HTML: 1503

• SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival

  Stergios Intzes, Marianthi Symeonidou, Konstantinos Zagoridis, Aikaterini Pentidou, Spanoudakis Emmanouil

  e2021006

  2021-01-01

  https://doi.org/10.4084/mjhid.2021.006

  2260

  PDF: 913

  HTML: 375

• The possible role of chronic infection in the etiopathogenesis of a case of 5q-syndrome associated with tuberculosis and abnormality of the X chromosome.

  Lubomir Mitev

  e2022079

  2022-10-29

  https://doi.org/10.4084/MJHID.2022.079

  1597

  PDF: 578

  HTML: 317

• PROGNOSTIC IMPACT OF IMMUNOHISTOCHEMICAL P53 EXPRESSION IN BONE MARROW BIOPSY IN HIGHER RISK MDS: A PILOT STUDY

  Alfredo Molteni, Emanuele Ravano, Marta Riva, Michele Nichelatti, Laura Bandiera, Lara Crucitti, Mauro Truini, Roberto Cairoli

  e2019015

  2019-02-26

  https://doi.org/10.4084/mjhid.2019.015

  1979

  PDF: 1038

  HTML: 353

• RARE CYTOGENETIC ABNORMALITIES IN MYELODYSPLASTIC SYNDROMES

  Julie Schanz, Friederike Braulke, Detlef Haase

  e2015034

  2015-04-23

  https://doi.org/10.4084/mjhid.2015.034

  3966

  PDF: 1761

  HTML: 11937

  Figures Haase: 275

• LYMPHOCYTES IN PATIENTS WITH CHRONIC ACTIVE EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1 EXPRESSION AND A PREVAILING TH2 IMMUNE RESPONSE. EPSTEIN-BARR VIRUS INFECTION EXHIBITED ELEVATED PD-1/PD-L1

  kang sun

  e2024037

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.037

  3054

  PDF: 1174

  HTML: 135

• IS IT POSSIBLE TO PREDICT TUMOR PROGRESSION THROUGH GENOMIC CHARACTERIZATION OF MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA? MONOCLONAL GAMMOPATHY AND SMOLDERING MULTIPLE MYELOMA

  Ugo Testa, Prof. Leone, Dr. Elvira Pelosi, Dr. Germana Castelli, Prof, Valerio De Stefano

  e2024044

  2024-04-30

  https://doi.org/10.4084/MJHID.2024.044

  2679

  PDF: 1250

  HTML: 171

• EFFICACY AND SAFETY OF THALIDOMIDE IN PATIENTS WITH TRANSFUSION-DEPENDENT β-THALASSEMIA: A SYSTEMATIC REVIEW, META-ANALYSIS AND GRADE EVALUATION

  Jialian Li, Ping Ji, Qinyue Zhong, Lin Dong, Hai Yi, Baiyu Chen, Xu Zhang, Tingting Duan

  e2026033

  2026-04-30

  https://doi.org/10.4084/MJHID.2026.033

  407

  PDF: 385

  Suppl. Files: 97

  HTML: 126

• CURRENT KNOWLEDGE ON HIV-ASSOCIATED PLASMABLASTIC LYMPHOMA

  Michele Bibas, Jorge J Castillo

  e2014064

  2014-10-22

  https://doi.org/10.4084/mjhid.2014.064

  2729

  PDF: 1710

  HTML: 2458

  Table1: 258

• THERAPY-RELATED MYELOID NEOPLASMS: PREDISPOSITION AND CLONAL EVOLUTION T-AML predisposition

  Emiliano Fabiani, Dr. Falconi, Dr. Cristiano, Dr. Hajrullaj, Dr. Falconi, Prof. Leone, Prof. Voso

  e2023064

  2023-10-30

  https://doi.org/10.4084/MJHID.2023.064

  1571

  PDF: 1005

  HTML: 262

• ALLOGENEIC TRANSPLANTATION FOR CHRONIC LYMPHOCYTIC LEUKEMIA

  Luca Laurenti, Michela Tarnani, Patrizia Chiusolo, Federica Sorà, Simona Sica

  e2010026

  2010-08-31

  https://doi.org/10.4084/mjhid.2010.026

  1515

  PDF: 866

  HTML: 1038

• EFFECTS OF DARATUMUMAB ON HEMATOPOIETIC STEM CELLS IN PATIENTS WITH MULTIPLE MYELOMA WHO ARE PLANNED TO RECEIVE AUTOLOGOUS TRANSPLANTATION: WHAT’S THE RELEVANCE?

  Pellegrino Musto, Dr. Nicola Sgherza

  e2024073

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.073

  1666

  PDF: 897

  HTML: 321

• TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML

  Ugo Testa, Dr. Germana Castelli, Dr. Elvira Pelosi

  e2023038

  2023-06-29

  https://doi.org/10.4084/MJHID.2023.038

  2410

  PDF: 1892

  HTML: 1011

• FEASIBILITY AND OUTCOME OF FIRST-LINE AUTOTRANSPLANT-BASED TREATMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS AGED > 65 YEARS: MONOCENTRIC RETROSPECTIVE REAL-WORLD ANALYSIS Outcomes of ASCT in NDMM elderly fit patients

  Paola Stefanoni, Monica Galli, Laura Paris, Alessandro Rambaldi, Nicola Pittalis, Gianluca Cavallaro, Chiara Pavoni

  e2024066

  2024-08-31

  https://doi.org/10.4084/MJHID.2024.066

  1124

  PDF: 672

  Html: 182

• Successful treatment of gastric relapse in multiple myeloma with bortezomib after autologous hematopoietic stem cell transplantation (autoHSCT)

  Serdar Sivgin

  e2013006

  2013-01-02

  https://doi.org/10.4084/mjhid.2013.006

  1235

  PDF: 677

  HTML: 3355

• ROLE AND TIMING OF HEMATOPOIETIC CELL TRANSPLANTATION FOR MYELODYSPLASTIC SYNDROME

  Teresa L Field, Claudio Anasetti

  e2010019

  2010-07-19

  https://doi.org/10.4084/mjhid.2010.019

  1458

  PDF: 727

  HTML: 1258